Department of Otorhinolaryngology, University of Brescia, Brescia, Italy.
Am J Rhinol Allergy. 2010 Jan-Feb;24(1):60-5. doi: 10.2500/ajra.2010.24.3397.
Because of a better understanding of the anatomy from an endoscopic perspective, the acquisition of surgical experience, and concomitant technological advances, endoscopic resection of the anterior skull base (ASB) and overlying dura has now become a reality, opening new possibilities in the management of sinonasal malignancies. Here, the authors review a series of 62 patients, the largest reported to date, who underwent endoscopic transnasal craniectomy (ETC) and endoscopic dural repair for the management of selected sinonasal malignancies. Special emphasis is placed on the surgical technique, technical tricks, choice of materials for endoscopic dural repair, postoperative management, and complications.
From 2004, 62 patients underwent ETC at two referral hospitals, which extended anteroposteriorly from the frontal sinus to planum sphenoidale and laterolaterally from the nasal septum to the lamina papyracea (unilateral resection, n = 28; 45%) or from papyracea to papyracea (bilateral resection, n = 34; 55%). Duraplasty with a three-layer technique was performed using the iliotibial tract and fat tissue.
The most frequent histotypes were adenocarcinoma (58%) and olfactory neuroblastoma (22%). Forty-five (73%) patients were previously untreated. The incidence of early (T1-2, Kadish A-B) and advanced (T3-4, Kadish C) tumors was similar. The complication rate was 15%, mostly cerebrospinal fluid leaks (13%). Its prevalence did not correlate with patient age, medical comorbidities, previous treatment, presence of ASB involvement, or whether ETC was mono- or bilateral, but tended to correlate with advanced tumor stage, dural involvement, and the period of treatment. After a mean follow-up of 17.5 months (range, 1-54 months), 58 (94%) patients had no evidence of disease.
In correctly selected patients with sinonasal tumors involving the ASB, ETC offers a less invasive alternative than resection by an open approach with an acceptable morbidity.
由于从内镜角度更好地了解解剖结构、获得手术经验以及伴随而来的技术进步,内镜下切除前颅底 (ASB) 和覆盖硬脑膜现在已成为现实,为治疗鼻腔鼻窦恶性肿瘤开辟了新的可能性。在这里,作者回顾了一组 62 例患者,这是迄今为止报告的最大系列,他们接受了内镜经鼻颅切除术 (ETC) 和内镜硬脑膜修复术治疗选定的鼻腔鼻窦恶性肿瘤。特别强调了手术技术、技术技巧、内镜硬脑膜修复材料的选择、术后管理和并发症。
自 2004 年以来,在两家转诊医院,62 例患者接受了 ETC,其从前额窦延伸到蝶骨平台,从鼻中隔向外侧延伸到纸样板(单侧切除,n=28;45%)或从纸样板到纸样板(双侧切除,n=34;55%)。使用阔筋膜和脂肪组织进行三层技术硬脑膜修复。
最常见的组织学类型是腺癌 (58%) 和嗅神经母细胞瘤 (22%)。45 例(73%)患者未经治疗。早期(T1-2,Kadish A-B)和晚期(T3-4,Kadish C)肿瘤的发生率相似。并发症发生率为 15%,主要为脑脊液漏(13%)。其发生率与患者年龄、合并症、既往治疗、ASB 受累情况以及 ETC 是单侧还是双侧无关,但与肿瘤晚期、硬脑膜受累和治疗期有关。平均随访 17.5 个月(范围,1-54 个月)后,58 例(94%)患者无疾病证据。
在正确选择的涉及 ASB 的鼻腔鼻窦肿瘤患者中,ETC 提供了一种比开放手术切除更具侵入性的替代方法,其发病率可接受。